CLAIMS

What is claimed is:

1. Use of a pharmacologic agent in the manufacture of a medicament for treating a patient having a neurologic condition by synaptic pathway training comprising steps:

    synaptic pathways are to be activated within an area of the patient's brain with the use of a pharmacologic agent, wherein the activating step increases synaptic pathways and synaptic volume; and

    the activated synaptic pathways are to be stimulated with a non-pharmacological treatment, wherein prior to the stimulating step there is a selecting step wherein the non-pharmacological treatment is chosen based upon its efficacy in maintaining said synaptic pathways and volume.

2. The use of claim 1, wherein prior to the activating step there is a step of choosing the pharmacological agent based upon the agent's effectiveness in increasing synaptic pathways and synaptic volume in an area of the brain associated with the neurological condition.

3. The use of claim 1, wherein the pharmacologic agent is a hallucinogenic.

4. The use of claim 2, including interviewing the patient to determine whether the dosage was sufficient to increase synaptic pathways and synaptic volume.

5. The use of claim 4, where an increased dosage is to be administered, when it is determined the initial dosage was insufficient.

6. The use of claim 4, wherein the neurologic condition is depression.

7. The use of claim 4, wherein the neurologic condition is bipolar disorder.

8. The use of claim 4, wherein the neurologic condition is post-traumatic stress disorder.

9. The use of claim 1, wherein the neurological condition is alcoholism.

10. The use of claim 1, wherein the stimulating step comprises performance of a cognitive training exercise.

* * * *